Join this Featured Workgroup!
Elite Investors

This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.

In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.

In your application messsage, please share your background and what you can contribute to the group.



Company Overview and News

0
Coface SA : Disclosure of trading in own shares (excluding the liquidity agreement) made between July 9th and July 13th 2018

2018-07-16 globenewswire
COFACE SA: Disclosure of trading in own shares (excluding the liquidity agreement) made between July 9th and July 13th 2018
COFA

0
Coface SA : Déclaration des transactions sur actions propres (hors contrat de liquidité) réalisées entre le 9 juillet et le 13 juillet 2018

2018-07-16 globenewswire
COFACE SA : Déclaration des transactions sur actions propres (hors contrat de liquidité) réalisées entre le 9 juillet et le 13 juillet 2018
COFA

0
Coface SA : Coface nomme Carmina Abad Sanchez à la tête de la région Amérique Latine

2018-07-16 globenewswire
Coface annonce aujourd'hui la nomination de Carmina Abad Sanchez en tant que nouveau directeur général de sa région Amérique Latine. Carmina rejoint le comité exécutif et rapporte à Xavier Durand, directeur général du Groupe. Elle succède à Bart Pattyn qui après avoir passé 17 ans chez Coface, a décidé de poursuivre sa carrière en dehors du Groupe. Au cours de ces dernières années, Bart a bâti une solide équipe de direction au Mexique et dans les différents pays de la région, qui continuera à piloter l'activité de la société dans la région sous la direction de Carmina.
COFA

0
Coface SA : Coface appoints Carmina Abad Sanchez to lead its Latin America region

2018-07-16 globenewswire
Coface announces today the appointment of Carmina Abad Sánchez as the new CEO, Latin America region. She joins the Executive committee and reports to Xavier Durand, Group CEO. She takes over from Bart Pattyn who after a long career with the company (17 years) has decided to pursue career opportunities outside of the Coface Group. During the past years, he has built a solid team of leaders across Mexico and the various countries of the region, which will continue to drive the company's agenda across the region under Carmina's leadership.
COFA

0
Coface SA : Disclosure of trading in own shares (excluding the liquidity agreement) made between July 2nd and July 6th 2018

2018-07-09 globenewswire
COFACE SA: Disclosure of trading in own shares (excluding the liquidity agreement) made between July 2nd and July 6th 2018
COFA

0
Coface SA : Déclaration des transactions sur actions propres (hors contrat de liquidité) réalisées entre le 2 juillet et le 6 juillet 2018

2018-07-09 globenewswire
COFACE SA : Déclaration des transactions sur actions propres (hors contrat de liquidité) réalisées entre le 2 juillet et le 6 juillet 2018
COFA

0
Coface SA : Déclaration du nombre total des droits de vote et du nombre d'actions composant le capital social au 30 juin 2018

2018-07-06 globenewswire
COFACE SA : Déclaration du nombre total des droits de vote et du nombre d'actions composant le capital social au 30 juin 2018
COFA

0
Coface SA : Disclosure of total number of voting rights and number of shares in the capital as at June 30th, 2018

2018-07-06 globenewswire
COFACE SA: Disclosure of total number of voting rights and number of shares in the capital as at June 30th, 2018
COFA

0
Coface SA : Bilan semestriel du contrat de liquidité de COFACE SA et transfert du contrat initialement contracté avec NATIXIS à ODDO BHF

2018-07-05 globenewswire
Bilan semestriel du contrat de liquidité de COFACE SA et transfert du contrat initialement contracté avec NATIXIS à ODDO BHF
COFA

0
Coface SA : Half-year statement of the liquidity agreement of COFACE SA and transfer of the initial contract with Natixis to ODDO BHF

2018-07-05 globenewswire
Half-year statement of the liquidity agreement of COFACE SA and transfer of the initial contract with Natixis to ODDO BHF
COFA

0
COFACE SA : Déclaration des transactions sur actions propres (hors contrat de liquidité) réalisées entre le 25 juin et le 29 juin 2018

2018-07-02 globenewswire
COFACE SA : Déclaration des transactions sur actions propres (hors contrat de liquidité) réalisées entre le 25 juin et le 29 juin 2018
COFA

0
COFACE SA: Disclosure of trading in own shares (excluding the liquidity agreement) made between June 25th and June 29th 2018

2018-07-02 globenewswire
COFACE SA: Disclosure of trading in own shares (excluding the liquidity agreement) made between June 25th and June 29th 2018
COFA

0
Coface cède sa participation dans Cofacrédit

2018-06-27 globenewswire
Coface annonce aujourd'hui avoir cédé à Factofrance (Groupe Crédit Mutuel - CM11) sa participation de 36% au capital de Cofacrédit, société d'affacturage jusqu'ici détenue conjointement par les deux groupes. Cette participation minoritaire ne s'inscrit pas dans la stratégie de développement de Coface dans le domaine de l'affacturage. Cette cession est par ailleurs en ligne avec l'objectif du second pilier du plan Fit to Win, qui vise à une meilleure gestion du capital.
COFA

0
Coface sells its stake in Cofacrédit

2018-06-27 globenewswire
Coface announces today that it has ceded to Factofrance (Groupe Crédit Mutuel - CM11) its 36% stake in the capital of Cofacrédit, a factoring company previously jointly owned by the two groups. This minority stake was not core to Coface's development strategy in the factoring sector. The disposal is also in line with the objective of the second pillar of the company's Fit to Win plan, which aims to improve Coface's capital efficiency.
COFA

0
Coface SA : Déclaration des transactions sur actions propres (hors contrat de liquidité) réalisées entre le 18 juin et le 22 juin 2018

2018-06-25 globenewswire
COFACE SA : Déclaration des transactions sur actions propres (hors contrat de liquidité) réalisées entre le 18 juin et le 22 juin 2018
COFA

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...